03Jun/26
AI Drug Repurposing: When Time-to-Clinic Beats Novel MOA
Introduction: Why “Faster” Can Be More Valuable Than “First-in-Class” In drug discovery, novelty has long been treated as a strategic advantage. A new mechanism of action (MOA), a first-in-class target, or anRead More…